Furthermore, it has been demonstrated that concomitant mutations in KRAS and STK11 confer poor survival in lung adenocarcinoma patients [153] but their role in response to different kinds of treatments, including immunotherapy, need to be further elucidated. This evidence concerns the gene STK11 and lung adenocarcinoma.